Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
It is a recombinant nanoparticle protein-based vaccine
The company is the Clinical Research Organisation of Caplin Point Laboratories
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
Subscribe To Our Newsletter & Stay Updated
